Boeing 787 production signals improve in early January, UBS analysts say

UBS analysts report early-January indicators — including a 69% year-over-year increase in Dreamlifter flights over the 30 days to Jan. 9 and 18 Dreamlifter flights in the second week — point to recovering Boeing 787 production momentum with an implied production rate of ~5.4 aircraft/month (it had reached an implied 7.4/month pre-holidays). UBS models deliveries rising from ~6.5/month in Q4 2025 to 8/month by Q1 2026 and 10/month by Q1 2027, notes suppliers appear to be approaching Boeing's eight-per-month 2026 target, and maintains a Buy rating with a $275 12-month price target versus Boeing trading around $247.

Analysis

Market structure: A sustainable 787 ramp toward 8–10/mo materially benefits Boeing (BA) and direct suppliers (e.g., SPR) through higher OEM revenues and aftermarket spares, while exerting modest pricing pressure on competing widebody programs at Airbus over multi‑quarter delivery windows. Increased production tightens aircraft supply lead times vs. airline fleet plans, improving pricing power for Boeing on new widebody transactions but only if inventory drawdown converts to deliveries; implied Dreamlifter reads (5.4/mo now vs. 7.4/mo pre‑holidays) are the best near‑real‑time signal.

Risk assessment: Tail risks include FAA/quality inspections or a supplier shock that forces production reduction (low probability, high impact), macro airline demand softness reducing order uptake, or a delivery bottleneck that keeps build>ship (inventory glut). Near term (days–weeks) equity reaction is sentiment driven; medium term (3–9 months) depends on sustained Dreamlifter cadence and Cirium delivery confirmation; long term (12–24 months) hinges on suppliers hitting capacity to support 10/mo.

Trade implications: Favor asymmetric, time‑boxed exposure to BA upside with defined downside (equity + call spreads) and targeted supplier exposure (SPR) while keeping tails hedged; expect bond spreads to tighten on positive execution, reducing appeal of credit longs without operational proof. Use weekly Dreamlifter and Cirium delivery data as execution triggers: add on three consecutive weeks above implied 7/month, cut on two consecutive months <6/month.

Contrarian angles: Consensus assumes linear ramp—missed supplier infinite capacity is underpriced; success could be front‑loaded (inventory flush) and not durable, producing a sideways equity outcome despite higher flight counts. Historical parallels (post‑production restarts) show sharp initial sentiment rallies that faded without delivery conversion—trade with measurable production/delivery thresholds, not analyst optimism alone.

Key Decisions for Investors

• Establish a 2–3% long position in Boeing (BA) equity targeting $275 in 12 months (UBS PT) with an initial stop loss at 10% ($~222) and reduce to 1% exposure if Dreamlifter‑implied production stays <6 aircraft/month for two consecutive months.
• Purchase a 9–12 month call spread on BA to cap downside while retaining upside (size ~0.5% portfolio): e.g., Sep/Oct 2026 260/320 call spread (debit), close if BA >$300 or if implied production misses for two months.
• Initiate a 1–2% long position in Spirit AeroSystems (SPR) as a supplier play, target +30–40% upside if Boeing reaches 8–10/mo by Q1 2027; set a 20% stop loss and trim half on a 30% gain.
• Buy 12‑month downside protection sized ~0.5–1% portfolio: BA puts ~30% OTM (protects to ~$170) to hedge regulatory/grounding tail risk; alternatively use cheaper calendar put spreads to limit premium outlay.
• Use concrete data triggers to trade size: add to longs after three consecutive weeks of Dreamlifter implied rate >7/month or after Cirium records >8 monthly 787 deliveries; cut exposure after two consecutive months with implied rate <6/month.